Literature DB >> 10510406

C1q-containing immune complexes purified from sera of juvenile rheumatoid arthritis patients mediate IL-8 production by human synoviocytes: role of C1q receptors.

Z Khalkhali-Ellis1, G A Bulla, L S Schlesinger, D A Kirschmann, T L Moore, M J Hendrix.   

Abstract

Immune complexes that vary in size and composition are present in the sera and synovial fluid of juvenile rheumatoid arthritis (JRA) patients. They are believed to be potent inducers of the ongoing inflammatory process in JRA. However, the precise composition and role of these complexes in the pathophysiology of JRA remain unclear. We hypothesized that circulating ICs have the potential to interact with resident joint synovial fibroblasts (synoviocytes) and induce the expression of inflammatory cytokines. To test this hypothesis, cultures of synoviocytes from healthy individuals were treated with ICs isolated from the sera of JRA patients. Studies reported in this work demonstrate that IgM affinity-purified ICs from the sera of JRA patients contain IgM, C1q, IgG, and C3 to a variable extent. These ICs induce IL-8 mRNA and protein production in normal synoviocytes. Our data indicate that C1q in these ICs mediates, in part, IL-8 induction in synoviocytes. This is based on our findings of C1q-binding proteins for collagen stalks (cC1qR) and globular heads (gC1q-binding protein) of C1q in synoviocytes. In addition, collagen stalk and to some extent globular head fragments of C1q inhibit IC-mediated IL-8 induction in synoviocytes. Together, these findings provide evidence for a novel mechanism of IL-8 production by synoviocytes, which could play a key role in inflammation by recruiting leukocytes to synovial tissue and fluid-and subsequently contributing to joint disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510406

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen.

Authors:  Nirit Mor-Vaknin; Ferdinand Kappes; Amalie E Dick; Maureen Legendre; Catalina Damoc; Seagal Teitz-Tennenbaum; Roland Kwok; Elisa Ferrando-May; Barbara S Adams; David M Markovitz
Journal:  Arthritis Rheum       Date:  2011-02

2.  Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression.

Authors:  Patricia J Hunter; Kiran Nistala; Nipurna Jina; Ayad Eddaoudi; Wendy Thomson; Mike Hubank; Lucy R Wedderburn
Journal:  Arthritis Rheum       Date:  2010-03

3.  Alterations of the CD4(+), CD8 (+) T cell subsets, interleukins-1beta, IL-10, IL-17, tumor necrosis factor-alpha and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: preliminary observations.

Authors:  Mahmoud R Hussein; Nehal A Fathi; Azza M Ezz El-Din; Hewayda I Hassan; Fatemah Abdullah; Eman Al-Hakeem; Eman Abo Backer
Journal:  Pathol Oncol Res       Date:  2008-04-08       Impact factor: 3.201

4.  Novel approaches to gene expression analysis of active polyarticular juvenile rheumatoid arthritis.

Authors:  James N Jarvis; Igor Dozmorov; Kaiyu Jiang; Mark Barton Frank; Peter Szodoray; Philip Alex; Michael Centola
Journal:  Arthritis Res Ther       Date:  2003-11-06       Impact factor: 5.156

5.  Cryoglobulins as potential triggers of inflammation in schizophrenia.

Authors:  Andranik Chavushyan; Meri Hovsepyan; Anna Boyajyan
Journal:  Schizophr Res Treatment       Date:  2013-12-15

Review 6.  Immune Complexes in Juvenile Idiopathic Arthritis.

Authors:  Terry L Moore
Journal:  Front Immunol       Date:  2016-05-20       Impact factor: 7.561

7.  Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis.

Authors:  Xiaoyan Zhao; Nwora Lance Okeke; Orr Sharpe; Franak M Batliwalla; Annette T Lee; Peggy P Ho; Beren H Tomooka; Peter K Gregersen; William H Robinson
Journal:  Arthritis Res Ther       Date:  2008-08-18       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.